cell attachment and achieved a steady state when endothelial cells became confluent (72 hours). Thus, experiments were conducted after the electrical resistance achieved a steady state of 3000 ohms. Resistance data were normalized to the initial TER (ohms) and recorded over 20 hours.
Neutrophil transmigration
To assess neutrophil migration through TNF-α stimulated HMVEC-L, a static migration assay (CytoSelect™ Leukocyte Transmigration assay, Cambridge Biosciences) was used. HMVEC-L (1.6 x105/mL, 200 μL EGM-MV2 medium supplemented with 2% FBS, growth factors and antibiotics as per manufacturers recommendations Promocell, Heidelberg, Germany) were seeded onto the upper chamber of Transwell® filters (24-well size, 3 μm pore size; Corning, USA) and left for 72 hours at 37C, 5% CO2. Prior to assessing neutrophil transmigration, growth to confluence and monolayer integrity was confirmed using phase contrast microscopy, TER measurement, confocal microscopy (to assess adherens junction formation in HMVEC-L grown on Transwell inserts), and FITC-labelled dextran exclusion. At 72 hours, confocal microscopy of Transwell filters stained strongly for VE-cadherin (anti-goat Alexafluor 594, Santa Cruz Biotech: data not shown) suggesting intact adherens junctions in monolayers.
Transendothelial resistance increased over 72 hours, suggestive of monolayer integrity, and this effect was associated with lack of permeability to FITC-labelled albumin. After monolayer integrity was confirmed, Iscove's modified Dulbecco's medium (IMDM: 700 μL) was placed in the lower chamber. Cells were washed twice with PBS before the addition of GSK1995057 or dummy dAb (10nM) or vehicle control in medium for 1 hour prior to stimulation with TNF (10ng/mL)for 4 hours at 37C, 5% CO2. All conditions were performed in triplicate. Following a further 2 washes in PBS (to remove basal chemokine release from stimulated HMVEC-L), the medium in the lower chamber was changed to IMDM containing IL-8 (50 ng/mL; R&D Systems). Peripheral blood neutrophils were isolated from healthy volunteers using dextran sedimentation and discontinuous plasma-Percoll® gradient centrifugation, as previously described (E1).
Neutrophils were suspended at 1x106 cell/mL in serum-free IMDM, and Leukotracker™ (Cambridge Bioscience, UK) added at the manufacturer's recommended dilution. Cells were incubated at 37C, 5% CO2 for 1 hour, washed twice and re-suspended at 1x10 6 cells/mL in serum-free media; 200μL of this solution was added to the upper chamber, and neutrophils left to migrate for 3 hours. After 3 hours, the medium in the upper chamber was discarded and non-migratory cells removed with a cotton swab. The Transwell filter was then placed in a well containing lysis buffer and medium from the lower chamber containing migrated neutrophils. The plate was gently shaken for 5 minutes at room temperature before the fluorescence was read, in triplicate, at 480 nm/520 nm.
Endothelial ligand cell surface expression
HMVEC-L were seeded into 6-well plates (1.2 x 10 5 cells/well) and grown to confluence over 3 days (37°C, 5% CO2). The effect of TNFR1 antagonism on adhesion molecule expression was assessed following 1 hour preincubation with GSK1995057 or dummy dAb (10nM) or vehicle control followed by TNF (10ng/mL) stimulation for 4 hours. Cells were washed three times with Hanks Balanced Salt Solution, and harvested using non-enzymatic cell dissociation buffer (Sigma-Aldrich). The cell suspension was placed on ice and centrifuged at 400 g (5 minutes, 4C). The supernatant was removed and the cell pellet re-suspended in blocking buffer (5% fetal bovine serum, 0.5% bovine serum albumin in PBS) for 10 minutes at 4C. Antibodies to E-selectin (clone HCD62E, Biolegend), VCAM-1 (Clone STA, Biolegend) and ICAM-1 (Clone HA58, Biolegend), along with appropriate isotype and unstained controls were added and the cell incubated in the dark (30 minutes, 4C). Cells were washed twice and re-suspended in stain buffer (PBS +1% FBS + 0.09% sodium azide) before being transferred to FACS tubes. Samples were analyzed on a FACSCanto™ II flow cytometer (BD Biosciences).
Preclinical study in cynomolgus monkeys

Study Design & Procedures
Adult male Cynomolgus monkeys weighing between 3.6-5.7kg, were chosen for this study because it is a species that has shown pharmacologic responses to GSK1995057, and is commonly used for efficacy studies in the LPS-challenge model. Determination of group size was based on feasibility but with a target of including at least n=5 animals per treatment group based on an assessment of the variability of planned BAL endpoints from historical data in this model. Animals were assigned to treatment groups by the study director based on baseline response to LPS in Session 1 to ensure a balance of LPS responsiveness across treatment groups following the design schematic The doses of vehicle (Group 2) and GSK1995057 (Groups 3-5) were delivered by aerosol inhalation using a Pari LC jet nebulizer (Pari, USA) at a dose volume of 0.5 mL/kg. Each treatment was delivered at a calculated dose time determined for each animal based on body weight. Therefore, based on mean body weights at the time of dosing, the total delivered doses (i.e. nominal doses) in this study were 1.2mg of fluticasone propionate in Group 1, and 0.043mg, 0.45mg, and 4.7mg of GSK1995057 in Groups 3, 4, and 5, respectively. Dose times ranged between 9 and 14.25 minutes and an additional 3.5 mL of the dosing formulation was added to the nebulizer chamber for each dose to compensate for dead space and possible foaming during the nebulisation.
Bronchoalveolar lavage
A paediatric fiberoptic bronchoscope was wedged into a segmental bronchus, and 3 aliquots of sterile 0.9% saline (20 mL) instilled. Bronchoalveolar lavage return was measured, and samples placed on ice until transferred to the laboratory for processing. BALF was centrifuged and the supernatant removed and stored at -80C for subsequent analysis. The cell pellet was re-suspended in phosphate buffered saline (2 mL). Cytospins were prepared and stained with Wright-Giemsa, before a minimum of 200 nucleated cells were counted to determine the differential cell counts.
Clinical trial in healthy volunteers
Subjects
Healthy subjects were recruited by advertising. Screening consisted of a history and physical examination, blood investigations, ECG, and spirometry (the full inclusion and exclusion criteria and study schedule are outlined in Supplementary Table E1 and Supplemental data E1).
Study Design
The study was a randomized, placebo-controlled clinical trial. The participants, site investigators and the staff performing the laboratory assays were blinded to the treatment allocation. The site clinical trials pharmacist and central GSK study team were unblinded to treatment allocation. Eligible subjects received a unique subject number.
Subjects were assigned to receive a total nebulised dose of GSK1995057 (26 mg) or identical placebo (1:1) in accordance with the randomization schedule generated by Clinical Pharmacology and Biometrics at GSK. When an eligible subject was recruited, the clinical trials pharmacist allocated the subject to the designated treatment group, maintaining blinding. Details of the study medication are given in Supplementary table 2. The nebulizer solutions had an identical appearance. Study drug was administered using a Pari eFlow nebuliser. One hour after the study medicine was taken, subjects inhaled LPS (total dose 50 μg) using a large-volume reservoir delivery system as described (E2). BAL was performed 6 hours after LPS inhalation (7 hours after dosing GSK1995057). Blood was collected as defined in the schedule of events in the online supplement (Supplementary Table 1 ). LPS inhalation (Escherichia coli serotype O26:B6; Sigma Chemicals, Poole, Dorset, UK) was dissolved in endotoxin free sterile 0.9% saline and inhaled via an automatic inhalation-synchronized dosimeter nebuliser (Spira, Hameenlinna, Finland). This delivers particles of a mass median aerodynamic diameter (MMAD) of 10 μm as described previously (E3). The dosimeter produces a calibrated aerosol of 8 μL at each slow inhalation starting from functional residual capacity (FRC) to total lung capacity (TLC). Each subject performed five successive inhalations of the LPS solution (1.25 mg/mL) through the mouthpiece with a nose clip in place. The total dose of inhaled LPS was 50 μg.
The BAL procedures, as well as the processing of BALF and blood, were performed as described below. Subjects stayed overnight in a clinical research unit following dosing with LPS.
Bronchoalveolar lavage
Bronchoalveolar lavage was performed 6 hours after LPS inhalation according to standard guidelines (E4). Three successive 60 mL aliquots of 0.9% saline were instilled into a sub-segment of the right middle lobe and each aspirated immediately with low suction. Bronchoalveolar lavage fluid (BALF) return was measured and immediately placed on ice until transferred to the laboratory for processing. BALF was centrifuged at 900g for 5 minutes at 4°C.
The supernatant was removed and stored at -80C for subsequent analysis. The cell pellet was re-suspended in phosphate buffered saline (PBS: 10 mL) supplemented with 1% bovine serum albumin (BSA) (Sigma Chemicals).
Total cell count was determined using a hemocytometer. Cell viability was measured by the ability of live cells to exclude Trypan blue. Cytospins were prepared and stained with Speedy-Diff (Clin-Tech Ltd, UK). A single cytologist who was blinded to treatment allocation performed the differential cell counts. Epithelial lining fluid (ELF) concentrations of GSK1995057 were derived by normalising to concentrations of ELF urea (E5).
Plasma samples
Blood was collected into K3 EDTA tubes, mixed gently, and placed immediately on ice until processed. Blood was centrifuged at 1500g for 10 minutes at 4°C. The plasma was removed and stored at -80C for subsequent analysis.
Serum Samples
Blood was collected into serum separator tubes, mixed gently and maintained at ambient temperature for 30 minutes to 1 hour to allow for complete clotting before centrifugation at 1500g for 15 minutes at 4°C. The serum was removed and stored at -80C for subsequent analysis. Free and total sTNFR1 were measured to monitor the interaction of GSK1995057 with sTNFR1. The assay for free sTNFR1 detects sTNFR1 not bound to GSK1995057, whereas the assay for total sTNFR1 detects both free sTNFR1 and sTNFR1 bound to GSK1995057. No error bar shown in panel (a) for GSK1995057 group as all values measured were below the lower limit of quantification of the assay (61.73 pg/mL). 
Exclusion Criteria
A subject was not eligible for inclusion in this study if any of the following criteria applied:
1. A history of Hepatitis B, Hepatitis C or HIV infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
2. Current or chronic history of liver disease, or known hepatic or biliary abnormalities. 6. Current evidence or history of an influenza-like illness as defined by fever (>38 0 C) and two or more of the following symptoms within the last 7 days: cough, sore throat, runny nose, sneezing, limb/joint pain, headache, vomiting/diarrhoea in the absence of a known cause, other than influenza.
7. Corrected QT interval (QTc) >450msec.
8. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females.
9. Subject unwilling to abstain from alcohol consumption from 24 hours prior to dosing until discharge from the clinic, and for 24 hours prior to all other out-patient clinic visits.
10. Current or previous smokers.
11. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or
